[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@chuminhua432 "#esmo2025 oral Biokin/SystImmune EGFR x HER3 ADC Iza-Bren (BL-B01D1) Phase I global study of Iza-Bren (BL-B01D1) an EGFR x HER3 bispecific antibody-drug conjugate (ADC) in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and other solid tumors D1D8 Q3W is summarized in the table. Promising efficacy was observed at XXX mg/kg in multiple tumor types with confirmed ORR (cORR) of XXXX% including NSCLC (cORR XXXX% N=14; cORR XXXX% for EGFR mutant N=11 and cORR XXXX% for EGFR wildtype N=3) and BC (cORR XXX% N=3)"
X Link @chuminhua432 2025-10-13T09:58Z 2905 followers, 2311 engagements

"On Oct XX Biokin/SystImmune announced that the global Phase 2/3 pivotal registration clinical trial IZABRIGHT-Breast01 for its iza-bren (BL-B01D1 EGFRHER3 bispecific ADC) in collaboration with $BMY has achieved a milestone triggering the first $XXX million near-term contingent payment condition under the BMS collaboration agreement. The wholly-owned subsidiary SystImmune will receive the payment"
X Link @chuminhua432 2025-10-13T10:22Z 2905 followers, XXX engagements

"#Innovent Biologics' U.S. subsidiary Fortvita Biologics has registered a Phase X clinical trial for the small-molecule GLP-1 receptor agonist #IBI3032 The Phase X trial plans to enroll XX healthy participants divided into X cohorts with each cohort consisting of X participants receiving IBI3032 or placebo in a 6:2. According to information disclosed by Innovent at this year's JPM IBI3032 is an oral small-molecule GLP-1 receptor agonist"
X Link @chuminhua432 2025-08-14T13:10Z 2901 followers, 2027 engagements

"$ONC and $ABBV s Pharmacyclics have decided to voluntarily dismiss the patent lawsuit the Big Pharma firm brought against its competitor over their BTK inhibitors. BeOne announced the decision in a securities filing to HKSE. The move comes after the U.S. Patent and Trademark Office (USPTO) recently invalidated all claims of AbbVies patent No. 11672803 which underpinned the Illinois pharmas patent infringement lawsuit filed in 2023"
X Link @chuminhua432 2025-10-03T15:36Z 2902 followers, XXX engagements

"China Biopharma Tracker - September 2025 #financing #ChinabioTracker In Sept. China private biotech reported XX financing deals totaled $500m only XX disclosed the amounts the number and amount is similar to prior months Aug. 30/22 $560m Jul. 23/17 $481m The three months of Q3 marked a significant rebound in financing amounts following nearly three years of weakness. The biggest financing in Sept. is TJ Biopharma I-mab spin-off Chinese bio raised nearly RMB XXX million in Series C2 led by CITIC Capital. One biotech GenFleet Therapeutics completed its IPO in HKSE IPO application frenzy: 12"
X Link @chuminhua432 2025-10-07T15:53Z 2902 followers, 1177 engagements

"CF PharmaTech officially lists on the Hong Kong Stock Exchange today. Joint sponsors for this IPO are CITIC Securities and CMB International with an issue price of HK$14.75 per share and net proceeds of HK$525.4 million. CF PharmaTech opened at HK$47 per share closing at HK$38.50 up 161.02%"
X Link @chuminhua432 2025-10-08T12:37Z 2902 followers, XXX engagements

"Eccogene Inc. submitted its Hong Kong IPO listing application documents with joint sponsors Jefferies BofA Securities and CICC. Founded in 2018 Eccogene has pipeline including GLP-1 receptor agonists THR- agonists SSAO (VAP-1) inhibitors GIP receptor modulators and Amylin receptor agonists. Eccogene's Series C financing in Dec. 2023 resulted in a post-money valuation of $XXX million. In Nov. 2023 Eccogene signed an agreement with AstraZeneca on the small molecule oral GLP-1 agonist ECC5004. Eccogene granted AstraZeneca exclusive rights to develop and commercialize ECC5004 (for any indication)"
X Link @chuminhua432 2025-10-08T14:11Z 2902 followers, 1249 engagements

"$GSK announced that the NMPA has approved Shingrix (GSKs Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster) in adults aged XX years and over who are at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy. the previous indication for adults aged XX and older"
X Link @chuminhua432 2025-10-15T09:55Z 2900 followers, XXX engagements

"#3SBio published the Ph2 results of SSGJ-707 #SSGJ707 a bispecific antibody targeting PD-1 and VEGF as a monotherapy in patients with advanced NSCLC . Among the XX pts completed at least one efficacy evaluation ORR and DCR were XXXX% (8/27)/85.2% (23/27) 61.8%(21/34)97.1% (33/34) XXXX% (6/11)/90.9% (10/11) and XX% (1/4)/75% (3/4) at doses of 5mg/kg Q3W 10mg/kg Q3W 20mg/kg Q3W and XX mg/kg Q3W respectively. Select subgroups are summarized in SSGJ-707 10mg/kg Q3W. The ORR were XXXX% (12/22) and 75%(9/12) in non-squamous and squamous pts respectively"
X Link @chuminhua432 2025-05-23T08:08Z 2902 followers, 12K engagements

"Some media reported that Legend Biotech $LEGN has disbanded its Chinese sales and marketing team. On August XX 2024 #Carvykti (cilta-cel) was approved for marketing in #China becoming the sixth CAR-T cell therapy to be launched in China. In 2024 Carvykti's global sales revenue was $XXX million. $JNJ"
X Link @chuminhua432 2025-06-16T10:09Z 2901 followers, 1412 engagements

"#Minova Pharma completed a hundred-million RMB level Series B #financing exclusively led by IDG Capital. Minova's homegrown DCA (deoxycholic acid) injection wasapproved for market in China in June becoming China's first aproved fat-dissolving injection. The company continues to focus on the field of aesthetic-related diseases with new drugs for s androgenetic alopecia and photoaging set to enter clinical development in Q4 2025. In the field of mental health the anti-postpartum depression drug MI078 capsule has completed Phase II clinical studies"
X Link @chuminhua432 2025-08-25T06:12Z 2905 followers, XXX engagements

"#Akeso said in its H1 2025 report its lung cancer drug ivonescimab (PD-1/EGFR) for the first time clearly extended overall survival (OS) in a pivotal study. The final analysis of the Phase III HARMONi-A trial met its OS goal showing that ivonescimab delivered "a statistically significant and clinically meaningful OS benefit.""
X Link @chuminhua432 2025-08-27T02:31Z 2903 followers, 9739 engagements

"#Akeso announced that its independently developed first-in-class #bispecific #ADC #AK146D1 (Trop2/Nectin4 ADC) for the treatment of advanced solid tumors has completed the enrollment of its first patient in a Phase Ia clinical study in #China. The study is currently progressing in China Australia and other regions. AK146D1 is Akeso's first bispecific ADC to enter the clinical stage. AK146D1 received clinical trial approvals from the FDA the Australian TGA and China's NMPA"
X Link @chuminhua432 2025-08-28T09:10Z 2903 followers, 2776 engagements

"#MagicRNA announced the completion of nearly RMB100 million in Pre-A+ #financing led by IDG Capital. The funds will be used for the IND filing and IITs of the lead asset #HN2301. Founded in December 2021 MagicRN focuses on nucleic acid drug delivery and therapeutic mRNA innovative drugs. The company has developed a ionizable amino lipid library with the lipid (ILB3132) already commercialized. In 2023 MagicRNA successfully established an engineered cell delivery platform (Engineered Cell Targeted LNP EnC-LNP). The in vivo CAR-T HN2301 developed based on the EnC-LNP platform enter the clinical"
X Link @chuminhua432 2025-08-29T09:59Z 2903 followers, 7420 engagements

"#3SBio announced that its #IND application for #SA102 has been approved by #NMPA for the treatment of relapsed or refractory multiple myeloma. SA102 is a CS1/BCMA dual-target CAR-T therapies developed by Wuhan Sian Medical Tech. In Dec. 2023 3SBio and Sian signed a patent licensing agreement granting 3SBio exclusive rights in Greater China for the development registration manufacturing and commercialization of the drug. Previously SA102 completed an IIT at Wuhan Union Hospital. The study results showed that among all XX treated patients XX patients (ORR: 81%) achieved OR reaching minimal"
X Link @chuminhua432 2025-09-05T16:31Z 2903 followers, XXX engagements

"#Epigenic Therapeutics a clinical-stage innovative drug development company today announced the completion of a $XX million Series B round of #financing led by Lapam Capital with continued participation from existing investors Qiming Venture Partners and OrbiMed and addition of new investors including IFSC and a renowned investment firm in the industry. This round of funding will primarily support the ongoing clinical development of EPI-003 for chronic hepatitis B functional cure and EPI-001 for hypercholesterolemia treatment. Epigenic focuses on developing next-generation gene modulation"
X Link @chuminhua432 2025-09-08T09:51Z 2902 followers, 1066 engagements

"A rumor suggests that $BMY may be poised for a major adjustment in its #China operations. According to the content of a leaked email BMS has signed an agreement to sell its XX% stake in Shanghai Bristol-Myers Squibb Pharmaceutical Co. Ltd. (SASS) along with several related products manufactured and sold exclusively in the mainland China marketincluding Baraclude (entecavir) Bufferin Theragran Monopril (fosinopril) and Velosef (cephradine)to an affiliate of Hillhouse Investment Group (Highland Capital). The transaction is expected to be completed in early 2026 with the specific deal amount yet"
X Link @chuminhua432 2025-09-13T08:23Z 2901 followers, 13.7K engagements

"China Biopharma Tracker - September 2025 #apprvoal #ChinabioTracker Only X new novel drugs received their first marketing approval in September by China's NMPA both are from ex-China 1) Tzield (teplizumab) $SNY CD3 mab for type X diabetes 2) Fexuclue (fexuprazan) P-CAB Yangtze River Pharma licensed from Daewoong Pharma for gastroesophageal reflux disease X drugs approved for new indication including Mazdutide dual glucagon/GLP-1 receptor agonist for T2DM Innovent licensed the drug from $LLY And denosumab biosimiliar from Henlius Fosun' subsidiary appproved in both US and Europe in September"
X Link @chuminhua432 2025-10-06T14:38Z 2905 followers, 3326 engagements

"#esmo2025 oral Multitude Therapeutics CD44v9 ADC AMT-116 Updated ongoing phase I/II clinical trial results of AMT-116 a first-in-class anti-CD44v9 antibody-drug conjugate (ADC) in patients with advanced solid tumors X mg/kg Q2W was determined as the RP2D dose in AMT-116-02 Among EGFR wild-type NSCLC patients (n=20; squamous/non-squamous) the objective response rate was XX% (6/20 X confirmed PR) and the disease control rate was XX% (17/20). TRAEs Grade X occurred in XXXX% of patients"
X Link @chuminhua432 2025-10-13T10:05Z 2903 followers, 1004 engagements

"Kailera Therapeutics Announces $XXX Million Series B Financing Kailera Therapeutics details of which first emerged in May 2024 under the name Hercules CM NewCo emerged from stealth Tuesday with plans to develop a portfolio of GLP-1 drugs. The drugs were acquired from Jiangsu Hengrui Pharmaceuticals"
X Link @chuminhua432 2025-10-15T09:28Z 2903 followers, 1026 engagements

"$JNJ reported 2025 Q3 earnings XXX% sales increase to $XX billion BCMA CAR-T therapy Carvyktideveloped in partnership with Legend Biotechsaw significant sales growth. Carvykti achieved total sales of $XXX million in Q3 2025 marking an XXXX% yoy increase. Carvykti's sales have already surpassed $X billion this year totaling $XXXXX billion exceeded its full-year total from 2024 which was $XXX million"
X Link @chuminhua432 2025-10-15T09:43Z 2903 followers, 2763 engagements

"A good series by @FierceBiotech about $NVO vs KBP Biosciences founded by Zhenhua Huang FierceBiotech went through thousands of pages of sealed court documents"
X Link @chuminhua432 2025-10-16T14:55Z 2905 followers, XXX engagements

"$DNTH a clinical-stage bio announced it has entered into an exclusive #licensing agreement with Nanjing Leads Biolabs for DNTH212 (being developed in China by Leads Biolabs as LBL-047) a first and potentially best-in-class bifunctional BDCA2 and BAFF/APRIL inhibitor. DNTH212 is an investigational extended half-life bifunctional fusion protein. Now in Ph1. $XX million upfront + near-term milestone payments $X million milestone upon the initiation of a Dianthus-led Phase X study additional $XXX million in total development and regulatory approval milestones and sales-based milestones"
X Link @chuminhua432 2025-10-17T07:02Z 2905 followers, 1559 engagements

"$GILD s Kite Pharma is doubling down on in vivo CAR-T this time inking a deal worth up to $XXXX billion biobucks with biotech Pregene Biopharma. $XXX million upfront + $XXXX billion milestone Pregene also helped AstraZeneca-owned EsoBiotec design its in vivo CAR-T. The Big Pharma bought out EsoBiotec back in March for up to $X billion dollars"
X Link @chuminhua432 2025-10-17T07:36Z 2905 followers, 2262 engagements

"Kelun-BiotechBiopharmaceuticalannouncedthat the Company's HER2-directed ADC trastuzumab botidotin (A166) was approved for marketing by NMPA for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (BC) who have received one or more prior anti-HER2 therapy. Trastuzumab botidotinconjugates a novel monomethyl auristatin F(MMAF)derivative (a highly cytotoxic tubulin inhibitor Duo-5) via a stable enzyme-cleavable linker to a HER2 monoclonal antibody with a drug-to-antibody-ratio (DAR) of 2"
X Link @chuminhua432 2025-10-17T15:42Z 2905 followers, XXX engagements

"Today's 3rd biopharma out-licensing deal: Hansoh Pharma grants Roche an exclusive worldwide license (excluding the Chinese Mainland Hong Kong Macau and Taiwan) to its investigational CDH17-targeting ADC HS-20110. Hansoh Pharmawill receive an upfront payment of US$80 million and is eligible to receive milestone payments as well as royalties on potential future product sales. HS-20110 a CDH17-targeting ADCutilizing TOPOi payload. In Ph1 study for solid tumor"
X Link @chuminhua432 2025-10-17T15:55Z 2905 followers, 1728 engagements

"$IMAB announced its intention to pursue a Hong Kong IPO through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX). The Company intends to operate under the new name of NovaBridge Biosciences. The Company also announced the pending acquisition of VIS-101 a novel bifunctional biologic targeting VEGF-A and ANG2. The pending acquisition will be made by a newly formed subsidiary Visara Inc. (Visara) a NewCo focused on developing ophthalmic therapeutics for serious eye disorders and is expected to be completed later this month. VIS-101 (also named lASKG712) is developed by ASK pharma the"
X Link @chuminhua432 2025-10-17T16:56Z 2905 followers, 2396 engagements

"While $IMAB's press release describes VIS-101 "to be acquired by Visara" ASK Pharma's Chinese listing announcement refers to it as a licensing agreement in licensed territories. According to ASK its controlling subsidiary AskGene Pharma has entered into a licensing agreement with Visara. AskGene Pharma grants Visara rights of its ASK G712 (VIS-101) within the licensed territories. The licensed regions include Greater China Singapore Thailand Malaysia Indonesia Vietnam South Korea and India. Visara will pay AskGene a one-time non-refundable upfront payment of $X million within XX business days"
X Link @chuminhua432 2025-10-17T17:07Z 2905 followers, 1777 engagements